Recombinant Trop2 (Sacituzumab Biosimilar) 抗体
Quick Overview for Recombinant Trop2 (Sacituzumab Biosimilar) 抗体 (ABIN7795133)
抗原
抗体类型
适用
宿主
克隆类型
标记
应用范围
质量等级
-
-
Expression System
- Mammalian cells
-
原理
- Sacituzumab Biosimilar, Endotoxin 0.05 EU/mg
-
产品特性
- What is sacituzumab biosimilar research grade? Sacituzumab Biosimilar uses the same protein sequences as the therapeutic antibody sacituzumab. Sacituzumab govitecan is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer. Triple-negative breast cancer is a type of breast cancer that tests negative for estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2 (HER2) protein. Therefore, triple-negative breast cancer does not respond to hormonal therapy medicines or medicines that target HER2. Sacituzumab govitecan is a conjugate of the humanized anti-Trop-2 monoclonal antibody linked with SN-38, the active metabolite of irinotecan. Each antibody having on average 7.6 Molecules of SN-38 attached. SN-38 is too toxic to administer directly to patients, but linkage to an antibody allows the drug to specifically target cells containing Trop-2.
-
纯化方法
- Protein A or G affinity column
-
纯度
- >95 % by reducing SDS-PAGE
-
内毒素水平
- Less than 0.5 EU/mg of protein as determined by LAL method
-
免疫原
- Human Trop-2
-
-
-
-
应用备注
- Optimal working dilution should be determined by the investigator.
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- > 3 mg/mL
-
储存条件
- 4 °C,-20 °C
-
储存方法
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- Trop2 (Sacituzumab Biosimilar)
-
别名
- Sacituzumab Biosimilar
-
物质类
- Biosimilar
抗原
-